Transmission, pathogenesis and immunogenicity of SARS-CoV-2 in frontline healthcare workers: a national longitudinal cohort of 1320 participants

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:20 publications

Grant number: MR/V027883/1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $482,303.22
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    Dr. Ana Valdes
  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Nottingham
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Health PersonnelNurses and Nursing StaffPhysicians

Abstract

We want to know how many and which doctors and nurses have been infected with the virus (SARS-Cov2) that causes COVID-19 with or without symptoms. We have been collecting blood from 1320 healthcare workers on a weekly basis during the pandemic. We are analysing blood for antibodies against the virus. We will continue to measure their blood 10 times up to 6 months after the lockdown is lifted. This study will also allow us to know how the levels of antibodies in blood change over time and which of the antibodies are able to fight the virus. We will investigate whether individual characteristics, including genetics, age, sex, ethnicity, affect the length of time for which antibodies remain in blood at high enough levels to fight the virus. Among the doctors and nurses in our study we have people who have had a severe infection, others who have had mild symptoms and many with no symptoms. We will put all this information together to work out how healthcare workers develop antibodies against the virus and if this is affected by the severity of the symptoms is important. We will measure proteins and gene expression to identify how to effectively vaccinate and treat healthcare workers.

Publicationslinked via Europe PMC

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).

IgG N-glycome changes during the course of severe COVID-19: An observational study.

HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.

COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.

Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.

N-glycosylation of immunoglobulin G predicts incident hypertension.

Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.

Body mass index mediates the effect of the DASH diet on hypertension: Common metabolites underlying the association.